Germany · Delayed Price · Currency is EUR Esperion Therapeutics Statistics
Total Valuation
FRA:0ET has a market cap or net worth of EUR 753.36 million. The enterprise value is 1.19 billion.
| Market Cap | 753.36M |
| Enterprise Value | 1.19B |
Important Dates
The next estimated earnings date is Tuesday, March 3, 2026.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 235.43M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +18.70% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 47.14% |
| Float | 233.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.33 |
| PS Ratio | 2.91 |
| PB Ratio | -1.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.20 |
| EV / Sales | 4.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.00
| Current Ratio | 1.00 |
| Quick Ratio | 0.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.37 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.42% |
| Return on Invested Capital (ROIC) | -10.83% |
| Return on Capital Employed (ROCE) | -589.13% |
| Revenue Per Employee | 851,745 |
| Profits Per Employee | -296,710 |
| Employee Count | 304 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +50.40% |
| 50-Day Moving Average | 2.43 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 74.99 |
| Average Volume (20 Days) | 276 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.39 |
Income Statement
In the last 12 months, FRA:0ET had revenue of EUR 258.93 million and -90.20 million in losses. Loss per share was -0.46.
| Revenue | 258.93M |
| Gross Profit | 112.42M |
| Operating Income | -25.04M |
| Pretax Income | -90.20M |
| Net Income | -90.20M |
| EBITDA | -24.95M |
| EBIT | -25.04M |
| Loss Per Share | -0.46 |
Balance Sheet
The company has 78.79 million in cash and 512.22 million in debt, giving a net cash position of -433.43 million.
| Cash & Cash Equivalents | 78.79M |
| Total Debt | 512.22M |
| Net Cash | -433.43M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -384.69M |
| Book Value Per Share | -1.87 |
| Working Capital | 1.22M |
Cash Flow
| Operating Cash Flow | -79.51M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 43.42%, with operating and profit margins of -9.67% and -34.84%.
| Gross Margin | 43.42% |
| Operating Margin | -9.67% |
| Pretax Margin | -34.84% |
| Profit Margin | -34.84% |
| EBITDA Margin | -9.64% |
| EBIT Margin | -9.67% |
| FCF Margin | n/a |
Dividends & Yields
FRA:0ET does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.70% |
| Shareholder Yield | -18.70% |
| Earnings Yield | -11.97% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:0ET has an Altman Z-Score of -5.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.65 |
| Piotroski F-Score | 2 |